-
2
-
-
79960614571
-
-
American Diabetes Association. National Diabetes Fact Sheet. Available at: http://www. diabetes.org/diabetes-statistics/national-diabetes-fact-sheet. jsp. Accessed February 15, 2005.
-
National Diabetes Fact Sheet
-
-
-
3
-
-
0032972676
-
1999 Racial and ethnic differences in glycemic control of adults with type 2 diabetes
-
Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. 1999 Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403-408.
-
(1999)
Diabetes Care
, vol.22
, pp. 403-408
-
-
Harris, M.I.1
Eastman, R.C.2
Cowie, C.C.3
Flegal, K.M.4
Eberhardt, M.S.5
-
4
-
-
0026648961
-
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
-
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;15;267:7402-7405.
-
(1992)
J Biol Chem
, vol.267
, Issue.11
, pp. 7402-7405
-
-
Eng, J.1
Kleinman, W.A.2
Singh, L.3
Singh, G.4
Raufman, J.-P.5
-
5
-
-
0347360186
-
Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes
-
Nielsen LL,Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides. 2004;117: 77-88.
-
(2004)
Regulatory Peptides
, vol.117
, pp. 77-88
-
-
Nielsen, L.L.1
Young, A.A.2
Parkes, D.G.3
-
6
-
-
0028803336
-
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH sub 2-terminus in type II diabetic patients and in healthy subjects
-
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH sub 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126-1131.
-
(1995)
Diabetes
, vol.44
, pp. 1126-1131
-
-
Deacon, C.F.1
Nauck, M.A.2
Toft-Nielsen, M.3
Pridal, L.4
Willms, B.5
Holst, J.J.6
-
7
-
-
0037850667
-
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
-
Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26:2370-2377.
-
(2003)
Diabetes Care
, vol.26
, pp. 2370-2377
-
-
Fineman, M.S.1
Bicsak, T.A.2
Shen, L.Z.3
-
8
-
-
0031936954
-
Glucagon-like peptides
-
Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47:159-169.
-
(1998)
Diabetes
, vol.47
, pp. 159-169
-
-
Drucker, D.J.1
-
9
-
-
0038497464
-
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
-
Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082-3089.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 3082-3089
-
-
Kolterman, O.G.1
Buse, J.B.2
Fineman, M.S.3
-
10
-
-
15444367142
-
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
-
Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm. 2005;62:173-181.
-
(2005)
Am J Health-Syst Pharm
, vol.62
, pp. 173-181
-
-
Kolterman, O.G.1
Kim, D.D.2
Shen, L.3
Ruggles, J.A.4
Nielsen, L.L.5
Fineman, M.S.6
Baron, A.D.7
-
11
-
-
7444243454
-
Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
June 4-8 ; Orlando, Fla. Abstract 6-LB
-
DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A. Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [abstract]. Presented at: American Diabetes Association 64th Annual Scientific Sessions; June 4-8, 2004; Orlando, Fla. Abstract 6-LB.
-
(2004)
American Diabetes Association 64th Annual Scientific Sessions
-
-
DeFronzo, R.1
Ratner, R.2
Han, J.3
Kim, D.4
Fineman, M.5
Baron, A.6
-
12
-
-
7444228521
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
-
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, and the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
-
(2004)
Diabetes Care
, vol.27
, pp. 2628-2635
-
-
Buse, J.B.1
Henry, R.R.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
13
-
-
19444367290
-
Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea
-
June 4-8 ; Orlando, Fla. Abstract 10-LB
-
Kendall DM, Riddle MC, Dongliang Z, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea. Presented at: American Diabetes Association 64th Annual Scientific Sessions; June 4-8, 2004; Orlando, Fla. Abstract 10-LB.
-
(2004)
American Diabetes Association 64th Annual Scientific Sessions
-
-
Kendall, D.M.1
Riddle, M.C.2
Dongliang, Z.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
14
-
-
0033578476
-
Pharmacologic therapy for type 2 diabetes mellitus
-
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131: 281-303.
-
(1999)
Ann Intern Med
, vol.131
, pp. 281-303
-
-
DeFronzo, R.A.1
|